Paradigm Shift in the Treatment of Multiple Sclerosis

Initiating high-efficacy therapies as first-line treatment yields significantly better outcomes on average compared to a delayed escalation approach. Evidence suggests that the therapeutic window narrows over time, emphasizing the importance of early intervention. Consequently, the difference in outcomes between high-efficacy and intermediate-efficacy treatments becomes relatively small. While Denmark and Sweden employ different strategic approaches, both are grounded in the same body of clinical evidence.